Methods for selection of neoadjuvant treatment with chemotherapy for patients with hormone receptor-positive and HER2-negative with early breast cancer.

被引：0
|
作者：
Gasol Cudos, Ariadna
Morales Murillo, Serafin
Tuset Der-abrain, Noemi
Arbones Cid, Laura
Morera Morillo, Ester
Vilardell, Felip
Sanchez Guzman, Douglas
Canosa Morales, Carles
Mele Olive, Jordi
机构：
[1] Hosp Univ Arnau de Vilanova Lleida, Lleida, Spain
[2] Hosp Arnau Vilanova, GEICAM Spanish Breast Canc Grp, Lleida, Spain
[3] Univ Hosp Arnau de Vilanova, Lleida, Spain
[4] Hosp Arnau de Vilanova Lleida, Lleida, Spain
[5] Univ Hosp Arnau de Vilanova, Lerida, Spain
[6] Univ Hosp Arnau De Vilanova, Lleida, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12591
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer
    Niu, Nan
    Xue, Jinqi
    Qiu, Fang
    Chen, Guanglei
    Gu, Xi
    He, Guijin
    Cao, Shuo
    Yu, Xiaopeng
    Xu, Yongqing
    Yin, Jianqiao
    Han, Sijia
    Han, Ye
    Tang, Meiyue
    Zhao, Yafei
    Zheng, Ran
    Zheng, Xinyu
    Xu, Hong
    Liu, Caigang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
    Torrisi, Rosalba
    Marrazzo, Emilia
    Agostinetto, Elisa
    De Sanctis, Rita
    Losurdo, Agnese
    Masci, Giovanna
    Tinterri, Corrado
    Santoro, Armando
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
  • [3] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [4] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
  • [5] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [6] Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients
    Altundag, Kadri
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (03) : 999 - 999
  • [7] Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients
    Kadri Altundag
    Breast Cancer Research and Treatment, 2020, 184 : 999 - 999
  • [8] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
    Linnea T. Olsson
    Alina M. Hamilton
    Sarah C. Van Alsten
    Jennifer L. Lund
    Til Stürmer
    Hazel B. Nichols
    Katherine E. Reeder-Hayes
    Melissa A. Troester
    Breast Cancer Research and Treatment, 2024, 204 : 107 - 116
  • [9] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
    Olsson, Linnea T.
    Hamilton, Alina M.
    Van Alsten, Sarah C.
    Lund, Jennifer L.
    Sturmer, Til
    Nichols, Hazel B.
    Reeder-Hayes, Katherine E.
    Troester, Melissa A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (01) : 107 - 116
  • [10] EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
    Almstedt, K.
    Mendoza, S.
    Otto, M.
    Battista, M. J.
    Steetskamp, J.
    Heimes, A. S.
    Krajnak, S.
    Poplawski, A.
    Gerhold-Ay, A.
    Hasenburg, A.
    Denkert, C.
    Schmidt, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 137 - 146
12345